United Therapeutics Corp (UTHR)
United Therapeutics is a biotechnology company. Co. markets and sells four commercial therapies in the U.S. to treat pulmonary arterial hypertension: Tyvaso® (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin® (treprostinil) Injection (Remodulin); Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, which is approved for treatment of high-risk neuroblastoma, and the Remunity® Pump for Remodulin.
UTHR SEC Filing Email Alerts Service
| Company Name: |
United Therapeutics Corp |
| Stock buyback: |
UTHR buyback |
| Website: |
www.unither.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding UTHR: |
83 |
| Total Market Value Held by ETFs: |
$1.99B |
| Total Market Capitalization: |
$10.91B |
| % of Market Cap. Held by ETFs: |
18.27% |
|
|
April 19, 2024 • 7:45 AM Eastern
Strong Buy (3.50 out of 4)
100th percentile
|
|
Free UTHR Email Alerts:
